Terence Friedlander, MD

Chief of Hematology-Oncology at Zuckerberg San Francisco General; Associate Director for Cancer Research at ZSFG, Helen Diller Family Comprehensive Cancer Center; Associate Clinical Professor, Division of Hematology/Oncology, UCSF

Cancer Center Program Membership

Molecular Oncology

Research Summary

I am a clinical and translational oncologist specializing in cancers of the genitourinary tract, specifically bladder and prostate cancers. I also lead the Division of Hematology and Oncology at Zuckerberg San Francisco General Hospital and Trauma Center. My research is focused on understanding the basic biology of urologic malignancies and in developing novel therapeutic ways to treat disease. As a clinical academic oncologist I serve as principal investigator or co-investigator on a number clinical trials in advanced cancers including studies of immunotherapy, novel targeted therapy, and genetically guided therapy. All of our studies rely on strong collaboration between investigators spanning from the bench to the bedside to advance our understanding of how to best treat cancers for all our patients.

Education

Brown University, BA, 5/99
New York University School of Medicine, 2003, MD
UCSF Medical Center, 2003-2006, Residency
Utrecht University, Netherlands, 2007, Medical Ethics
UCSF Medical Center, 2007-2010, Oncology Fellowship

Honors & Awards

  • 2006
    Fullbright Scholarship in Medical Ethics, Netherlands-America Foundation
  • 2010
    ASCO Young Investigator Award, American Society of Clinical Oncology
  • 2011
    ASCO Merit Award, American Society of Clinical Oncology
  • 2012
    Physician Research Training Aaward, United States Department of Defense
  • 2012
    Young Investigator Award, Prostate Cancer Foundation
  • 2012
    Young Investigator Travel Award, Advances in Circulating Tumor Cells Symposium
  • 2019
    UCSF Division of Hematology and Oncology Teaching Award

Selected Publications

  1. Pollock Y, Zhang L, Kenfield SA, Van Blarigan EL, Rodvelt T, Rabow M, Macaire G, Weinberg R, Topp K, Friedlander T, Lin A, Fong L, Kim W, Ma B, Hough J, Lee M, Paciorek A, Ryan CJ, Chan JM, Small E, Aggarwal R. A multidisciplinary team-based approach with lifestyle modification and symptom management to address the impact of androgen deprivation therapy in prostate cancer: A randomized phase II study. Urol Oncol. 2021 Oct; 39(10):730.e9-730.e15.  View on PubMed
  2. Chu CE, Sjöström M, Egusa EA, Gibb EA, Badura ML, Zhu J, Koshkin VS, Stohr BA, Meng MV, Pruthi RS, Friedlander TW, Lotan Y, Black PC, Porten SP, Feng FY, Chou J. Heterogeneity in NECTIN4 Expression Across Molecular Subtypes of Urothelial Cancer Mediates Sensitivity to Enfortumab Vedotin. Clin Cancer Res. 2021 Sep 15; 27(18):5123-5130.  View on PubMed
  3. Sinha M, Zhang L, Subudhi S, Chen B, Marquez J, Liu EV, Allaire K, Cheung A, Ng S, Nguyen C, Friedlander TW, Aggarwal R, Spitzer M, Allison JP, Small EJ, Sharma P, Fong L. Pre-existing immune status associated with response to combination of sipuleucel-T and ipilimumab in patients with metastatic castration-resistant prostate cancer. J Immunother Cancer. 2021 05; 9(5).  View on PubMed
  4. de Kouchkovsky I, Zhang L, Philip EJ, Wright F, Kim DM, Natesan D, Kwon D, Ho H, Ho S, Chan E, Porten SP, Wong AC, Desai A, Huang FW, Chou J, Oh DY, Pruthi RS, Fong L, Small EJ, Friedlander TW, Koshkin VS. TERT promoter mutations and other prognostic factors in patients with advanced urothelial carcinoma treated with an immune checkpoint inhibitor. J Immunother Cancer. 2021 05; 9(5).  View on PubMed
  5. Chen E, Cario CL, Leong L, Lopez K, Márquez CP, Li PS, Oropeza E, Tenggara I, Cowan J, Simko JP, Kageyama R, Wells DK, Chan JM, Friedlander T, Aggarwal R, Paris PL, Feng F, Carroll PR, Witte JS. Cell-Free DNA Detection of Tumor Mutations in Heterogeneous, Localized Prostate Cancer Via Targeted, Multiregion Sequencing. JCO Precis Oncol. 2021; 5.  View on PubMed
  6. Greene C, Barlesi B, Tarroza-David S, Friedlander T. Improved Control of Tyrosine Kinase Inhibitor-Induced Diarrhea with a Novel Chloride Channel Modulator: A Case Report. Oncol Ther. 2021 Jun; 9(1):247-253.  View on PubMed
  7. Balcerek J, Trejo E, Levine K, Couey P, Kornberg ZV, Rogine C, Young C, Li PJ, Shy BR, Taylor JE, Bakhtary S, Friedlander T, Lynch KL, Bern C, Esensten JH. Hospital-Based Donor Recruitment and Predonation Serologic Testing for COVID-19 Convalescent Plasma. Am J Clin Pathol. 2021 Mar 15; 155(4):515-521.  View on PubMed
  8. Chen E, Cario CL, Leong L, Lopez K, Márquez CP, Chu C, Li PS, Oropeza E, Tenggara I, Cowan J, Simko JP, Chan JM, Friedlander T, Wyatt AW, Aggarwal R, Paris PL, Carroll PR, Feng F, Witte JS. Cell-free DNA concentration and fragment size as a biomarker for prostate cancer. Sci Rep. 2021 Mar 03; 11(1):5040.  View on PubMed
  9. Amara D, Wisel SA, Braun HJ, Collisson EA, Friedlander T, Worner G, Roll GR, Hirose R, Stock PG. Metastatic Donor-derived Malignancies Following Simultaneous Pancreas-kidney Transplant: Three Case Reports and Management Strategies. Transplant Direct. 2021 Jan; 7(1):e636.  View on PubMed
  10. Atreya CE, Collisson EA, Park M, Grenert JP, Behr SC, Gonzalez A, Chou J, Maisel S, Friedlander TW, Freise CE, Shoji J, Semrad TJ, Van Ziffle J, Chin-Hong P. Molecular Insights in Transmission of Cancer From an Organ Donor to Four Transplant Recipients. J Natl Compr Canc Netw. 2020 11; 18(11):1446-1452.  View on PubMed
  11. Ott PA, Hu-Lieskovan S, Chmielowski B, Govindan R, Naing A, Bhardwaj N, Margolin K, Awad MM, Hellmann MD, Lin JJ, Friedlander T, Bushway ME, Balogh KN, Sciuto TE, Kohler V, Turnbull SJ, Besada R, Curran RR, Trapp B, Scherer J, Poran A, Harjanto D, Barthelme D, Ting YS, Dong JZ, Ware Y, Huang Y, Huang Z, Wanamaker A, Cleary LD, Moles MA, Manson K, Greshock J, Khondker ZS, Fritsch E, Rooney MS, DeMario M, Gaynor RB, Srinivasan L. A Phase Ib Trial of Personalized Neoantigen Therapy Plus Anti-PD-1 in Patients with Advanced Melanoma, Non-small Cell Lung Cancer, or Bladder Cancer. Cell. 2020 10 15; 183(2):347-362.e24.  View on PubMed
  12. Kwon DH, Friedlander TW. Does One Size Fit All? Re-evaluating Prostate-specific Antigen Progression Thresholds for Clinical Trials. Eur Urol. 2020 12; 78(6):854-855.  View on PubMed
  13. Cario CL, Chen E, Leong L, Emami NC, Lopez K, Tenggara I, Simko JP, Friedlander TW, Li PS, Paris PL, Carroll PR, Witte JS. A machine learning approach to optimizing cell-free DNA sequencing panels: with an application to prostate cancer. BMC Cancer. 2020 Aug 28; 20(1):820.  View on PubMed
  14. Oh DY, Kwek SS, Raju SS, Li T, McCarthy E, Chow E, Aran D, Ilano A, Pai CS, Rancan C, Allaire K, Burra A, Sun Y, Spitzer MH, Mangul S, Porten S, Meng MV, Friedlander TW, Ye CJ, Fong L. Intratumoral CD4+ T Cells Mediate Anti-tumor Cytotoxicity in Human Bladder Cancer. Cell. 2020 06 25; 181(7):1612-1625.e13.  View on PubMed
  15. Posadas EM, Chi KN, de Wit R, de Jonge MJA, Attard G, Friedlander TW, Yu MK, Hellemans P, Chien C, Abrams C, Jiao JJ, Saad F. Pharmacokinetics, Safety, and Antitumor Effect of Apalutamide with Abiraterone Acetate plus Prednisone in Metastatic Castration-Resistant Prostate Cancer: Phase Ib Study. Clin Cancer Res. 2020 07 15; 26(14):3517-3524.  View on PubMed
  16. Flaig TW, Spiess PE, Agarwal N, Bangs R, Boorjian SA, Buyyounouski MK, Chang S, Downs TM, Efstathiou JA, Friedlander T, Greenberg RE, Guru KA, Guzzo T, Herr HW, Hoffman-Censits J, Hoimes C, Inman BA, Jimbo M, Kader AK, Lele SM, Michalski J, Montgomery JS, Nandagopal L, Pagliaro LC, Pal SK, Patterson A, Plimack ER, Pohar KS, Preston MA, Sexton WJ, Siefker-Radtke AO, Tward J, Wright JL, Gurski LA, Johnson-Chilla A. Bladder Cancer, Version 3.2020, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2020 03; 18(3):329-354.  View on PubMed
  17. Zuniga KB, Borno H, Chan JM, Van Blarigan EL, Friedlander TW, Wang S, Zhang L, Kenfield SA. The Problem of Underrepresentation: Black Participants in Lifestyle Trials Among Patients with Prostate Cancer. J Racial Ethn Health Disparities. 2020 10; 7(5):996-1002.  View on PubMed
  18. Kwon DH, Friedlander T. A TITAN step forward: apalutamide for metastatic castration-sensitive prostate cancer. Ann Transl Med. 2019 Dec; 7(Suppl 8):S364.  View on PubMed
  19. O'Donnell PH, Arkenau HT, Sridhar SS, Ong M, Drakaki A, Spira AI, Zhang J, Gordon MS, Degboe AN, Gupta AK, Mukhopadhyay P, Huang W, Abdullah SE, Angra N, Roskos LK, Guo X, Friedlander T. Patient-reported outcomes and inflammatory biomarkers in patients with locally advanced/metastatic urothelial carcinoma treated with durvalumab in phase 1/2 dose-escalation study 1108. Cancer. 2020 01 15; 126(2):432-443.  View on PubMed
  20. Friedlander TW, Welty C, Anantharaman A, Schonhoft JD, Jendrisak A, Lee J, Li P, Hough J, Stromlund A, Edwards M, Sangar S, Kobayashi Y, Simko J, Farrokhian N, Lindquist K, Greene S, Ontiveros P, Graf R, Rodriquez A, Suraneni M, Wang Y, Landers M, Carroll P, Cooperberg MR, Dittamore R, Paris PL. Identification and Characterization of Circulating Tumor Cells in Men Who have Undergone Prostatectomy for Clinically Localized, High Risk Prostate Cancer. J Urol. 2019 10; 202(4):732-741.  View on PubMed

Go to UCSF Profiles, powered by CTSI